Fact based stock research
Align (NasdaqGS:ALGN)


Align stock research in summary

aligntech.com


Align shares have a BUY rating. They show above average growth and are safely financed, but are bad value. We recommend buying and holding Align shares.


Latest Obermatt Ranks


Country USA
Industry Health Care Supplies
Index NASDAQ, S&P 500, D.J. US Medical Equipment
Size class X-Large

June 8, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock



Research History: Align

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
25
17
10
6
STOCK GROWTH RANKS
37
100
94
92
STOCK SAFETY RANKS
81
66
1
67
COMBINED STOCK RANKS
30
72
12
75

Last update of Combined Rank: 8-Jun-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Align in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 8-Jun-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Align; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
48
86
92
95
PROFIT GROWTH
47
10
10
67
STOCK RETURNS
51
97
95
98
CONSOLIDATED RANK: GROWTH
37
100
94
92

Financial reporting date of Growth Rank: 31-Mar-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Align.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
80
65
59
61
REFINANCING
1
8
2
4
LIQUIDITY
94
91
94
100
CONSOLIDATED RANK: SAFETY
81
66
1
67

Financial reporting date of Safety Rank: 31-Mar-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Align and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Align from June 8, 2018.